Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Active, not recruiting · Phase 3 · NCT03969004
Conditions: Cutaneous Squamous Cell Carcinoma
At a glance
- Research payments reported, 2025
- $1.0M
- U.S. investigators named
- 18
- Sites paid
- 18
- Planned or actual enrollment
- 415
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Cemiplimab (drug), Placebo (drug)
- Dates
- Started 2019-06-04; completion 2028-01-07
- Results posted
- Not yet
The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT). The secondary objectives of the study are: * To compare the overall survival (OS) of high-risk CSCC patients treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and RT * To compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from locoregional recurrence (FFLRR) after surgery and RT * To compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from d…
From ClinicalTrials.gov, last updated 2026-03-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $1.0M in research payments for this study in 2025 (277 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ashish V. Chintakuntlawar, MD, PHD Medical Oncology · Scottsdale, AZ
- Vasu Divi, MD Facial Plastic Surgery · Stanford, CA
- Gino K. In, MD Hematology & Oncology · Los Angeles, CA
- Cesar Ochoa Perez, MD Hematology & Oncology · Plantation, FL
- Ann W. Silk, M.D. Medical Oncology · Boston, MA
- Paul L. Swiecicki, MD Medical Oncology · Ann Arbor, MI
- George Ansstas, MD Medical Oncology · Saint Louis, MO
- Jonathan A. Dyer, M.D. Dermatology · Columbia, MO
- Yungpo B. Su, MD Hematology & Oncology · Omaha, NE
- Lara Dunn, M.D. Medical Oncology · New York, NY
- Nikhil I. Khushalani, MD MBBS Medical Oncology · Buffalo, NY
- David R. Carr, M.D. Mohs Surgery · Gahanna, OH
- Joseph J. Drabick, MD Hematology & Oncology · Hershey, PA
- Joanna L. Walker, M.D. Dermatology · Providence, RI
- Meredith A. Mckean, M.D. Hematology & Oncology · Nashville, TN
- Daniel Y. Wang, M.D. Hematology & Oncology · Houston, TX
- Varinder Kaur, MD Medical Oncology · Charlottesville, VA
- Vishal A. Patel, MD Dermatology · Lansdowne, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Hospital of Univ of Pennsylvania, PA $176,219
- The Ohio State University $147,762
- University of Virginia Medical Center, VA $124,442
- University of Texas Southwestern Medical Center $93,419
- Board of the Leland Stanford $89,603
- University of Southern California $58,438
- $56,140
- University of Missouri Health Care, MO $50,122
- Pennsylvania State University $41,413
- Dana Farber Mass General Brigham Cancer Care Inc $31,649
- Medical Faculty Associates Inc $28,402
- Sarah Cannon Research Institute LLC $23,650
- Washington University $22,767
- The Nebraska Methodist Hospital, NE $17,684
- Memorial Sloan Kettering Cancer Center $13,296
- Mayo Clinic Hospital, AZ $11,800
- Miami Cancer Institute at Baptist Health Inc $7,910
- Moffitt Cancer Center $6,078
- University of Michigan Health System, MI $3,674
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.